Here is the improved version while preserving the original meaning and formatting: Ca Atra (Note: Since “Ca Atra” appears to be a proper name or title with no additional context provided, I’ve kept it unchanged. The text remains identical as there are no improvements needed for a standalone proper noun.)

✅ Treats Acute Promyelocytic Leukemia
✅ Promotes Cancer Cell Death
✅ Inhibits Tumor Growth
✅ Enhances Chemotherapy Effectiveness
✅ Reduces Cancer Symptoms

This product is currently out of stock and unavailable.

Ca Atra Softgel Capsule is a retinoid medication derived from vitamin A, primarily prescribed for treating acute promyelocytic leukemia (APL), a specific form of blood cancer. This therapeutic agent functions by inhibiting the proliferation of abnormal blood cells while promoting the development of healthy, mature blood cells in bone marrow.

For optimal results, take this capsule with meals at consistent times daily to maintain steady medication levels. Clinical improvement may require several weeks of continuous treatment – maintain regular dosing even if immediate effects aren’t apparent. Never exceed prescribed dosages as this won’t accelerate results but may intensify adverse reactions.

Common treatment-related effects include cephalalgia, pyrexia, xeroderma, and cutaneous eruptions. These typically subside with continued use as your system adapts. Should symptoms persist or cause discomfort, consult your prescribing physician about potential dosage adjustments. Serious complications occur infrequently.

Photosensitivity represents a notable consideration – minimize direct sun exposure during therapy. Maintain hydration and use appropriate moisturizers to counteract potential xerostomia, cheilitis, and ocular dryness. The medication may increase cutaneous fragility; therefore, avoid depilatory waxing and laser procedures throughout treatment. This teratogenic agent requires strict contraception – confirm pregnancy status before initiation and maintain reliable birth control during therapy.

THERAPEUTIC INDICATIONS

  • Management of acute promyelocytic leukemia (APL)

CLINICAL BENEFITS

In hematologic malignancies

This retinoid formulation demonstrates particular efficacy in ameliorating APL manifestations including hemorrhagic tendencies, recurrent infections, and profound fatigue. Its dual mechanism promotes hematopoiesis of functional blood components while suppressing leukemic cell proliferation. The delayed therapeutic onset necessitates patient adherence despite initial absence of observable improvement. Absolute contraindications include gestation and lactation due to established embryotoxic potential.

ADVERSE EFFECTS PROFILE

Most treatment-emergent reactions are transient and self-limiting, resolving with continued therapy as tolerance develops. Persistent or concerning symptoms warrant medical evaluation.

Frequently observed reactions

  • Cutaneous erythema
  • Cephalalgia
  • Febrile episodes
  • Xeroderma
  • Ostealgia
  • Dermatologic eruptions
  • Visual disturbances
  • Alopecia
  • Hyperhidrosis
  • Mucositis
  • Localized discomfort
  • Dermal irritation
  • Pharyngeal pain
  • Xerosis
  • Desquamation

ADMINISTRATION GUIDELINES

Administer precisely as directed by your hematologist/oncologist. Ca Atra Softgel Capsule requires concomitant food intake for optimal absorption and tolerability.

PHARMACODYNAMICS

As a vitamin A analog, this agent exerts differential effects on hematopoietic cells: suppressing leukemic blast proliferation while facilitating normal myeloid differentiation. This dual activity underlies its efficacy in APL management by restoring balanced hematopoiesis and eliminating malignant promyelocytes.

Medical Disclaimer:

This content undergoes rigorous medical review to ensure accuracy, but serves solely for informational purposes. It does not encompass all potential adverse effects, contraindications, or drug interactions. Never substitute this information for professional medical advice. Consult your treating physician regarding any health concerns or medication questions. Our aim is to facilitate informed healthcare discussions between patients and their providers, not to replace clinical judgment.

Strength

10 mg

Quantity

100 Capsule/s, 200 Capsule/s, 300 Capsule/s

Pharma Form

Soft Gelatin Capsules

Manufacturer

Jenome Biophar

Treatment

Acute promyelocytic leukemia

Generic Brand

Bicalutamide

Reviews

There are no reviews yet

Add a review
Here is the improved version while preserving the original meaning and formatting:

Ca Atra

(Note: Since "Ca Atra" appears to be a proper name or title with no additional context provided, I've kept it unchanged. The text remains identical as there are no improvements needed for a standalone proper noun.) Here is the improved version while preserving the original meaning and formatting: Ca Atra (Note: Since "Ca Atra" appears to be a proper name or title with no additional context provided, I've kept it unchanged. The text remains identical as there are no improvements needed for a standalone proper noun.)
Rating*
0/5
* Rating is required
* Answer is required
Your review
* Review is required
Name
* Name is required
Add photos or video to your review
* Please confirm that you are not a robot